Advances in mesenchymal stem cells therapy for tendinopathies  

作　　者：Xu-Feng Mao Xi-Qian Zhang Zhe-Yu Yao Hai-Jiao Mao 

机构地区：[1]Department of Orthopaedic Surgery,The First Affiliated Hospital of Ningbo University,Ningbo,315010,Zhejiang province,China

出　　处：《Chinese Journal of Traumatology》2024年第1期11-17,共7页中华创伤杂志（英文版）

基　　金：supported by the Medical Health Project of the Health Department of Zhejiang Province,grant number 2021KY1045;Ningbo Public Welfare Science and Technology Project,grant number 2021S104;Ningbo Major Science and Technology Project,grant number 2022Z133;Zhejiang Provincial Natural Science Foundation of China,grant number LBY23H180002.

摘　　要：Tendinopathies are chronic diseases of an unknown etiology and associated with inflammation.Mesenchymal stem cells(MSCs)have emerged as a viable therapeutic option to combat the pathological progression of tendinopathies,not only because of their potential for multidirectional differentiation and self-renewal,but also their excellent immunomodulatory properties.The immunomodulatory effects of MSCs are increasingly being recognized as playing a crucial role in the treatment of tendinopathies,with MSCs being pivotal in regulating the inflammatory microenvironment by modulating the immune response,ultimately contributing to improved tissue repair.This review will discuss the current knowledge regarding the application of MSCs in tendinopathy treatments through the modulation of the immune response.

关 键 词：Mesenchymal stem cells TENDINOPATHY IMMUNOMODULATION TREATMENT REVIEW 

分 类 号：R686.1[医药卫生—骨科学]